Lee v AstraZeneca: India’s Next David And Goliath Fight?
This article was originally published in PharmAsia News
Executive Summary
A 40% chance for success and mere "publicity stunt" are some of the sharp early reactions to the surprise compulsory license application in India for AstraZeneca's saxagliptin by Hyderabad-based Lee Pharma, though the little known firm appears confident that its arguments in favor of a license hold water.